DaVita Inc. (DVA)
After hours:
| Previous Close | 109.39 |
| Open | 108.57 |
| Bid | 110.48 x 800 |
| Ask | 111.10 x 800 |
| Day's Range | 107.24 - 111.02 |
| 52 Week Range | 94.38 - 136.48 |
| Volume | |
| Avg. Volume | 842,808 |
| Market Cap | 11.283B |
| Beta (5Y Monthly) | 1.24 |
| PE Ratio (TTM) | 12.93 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Renalytix Reports Full Year Fiscal 2021 Results
LONDON and SALT LAKE CITY, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX), (LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces its results for the twelve months ended 30 June 2021. Highlights: Regulatory & Reimbursement Government-wide contract granted by the U.S. General Services Administration for KidneyIntelX™ testing s
- GlobeNewswire
Miromatrix Welcomes Dr. John Barry as Vice President of Research and Development
EDEN PRAIRIE, Minn., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced the hiring of Dr. John Barry as Vice President of Research and Development. Dr. Barry will be leading the activities for the development of the Company's transplantable liver and kidney programs including the use of a bio-engineered liver in an
- GlobeNewswire
Miromatrix Announces Key Strategic Investors to Advance the Development of Bioengineered Livers and Kidneys
The biotechnology company working to eliminate the organ transplant waitlist outlines expansion of its clinical work, supported by IPO funds and Series C round, led by Baxter, CareDx, and DaVitaEDEN PRAIRIE, Minn., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save patients' lives and improve quality of life around the world, announced strategic investors invol
